Marcela V. Maus Sells 3,900 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus sold 3,900 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $3.38, for a total transaction of $13,182.00. Following the sale, the director now owns 23,752 shares in the company, valued at $80,281.76. This represents a 14.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

2seventy bio Stock Down 3.4 %

2seventy bio stock opened at $3.11 on Thursday. 2seventy bio, Inc. has a 52-week low of $1.53 and a 52-week high of $6.40. The firm’s fifty day moving average is $4.64 and its 200 day moving average is $4.46.

Analyst Ratings Changes

Separately, Morgan Stanley reduced their price target on 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Hedge Funds Weigh In On 2seventy bio

Several institutional investors have recently made changes to their positions in TSVT. Erste Asset Management GmbH purchased a new position in 2seventy bio during the third quarter valued at $25,000. Readystate Asset Management LP acquired a new stake in 2seventy bio in the 3rd quarter worth about $53,000. SkyView Investment Advisors LLC increased its stake in 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of 2seventy bio during the third quarter valued at approximately $64,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of 2seventy bio in the second quarter valued at approximately $52,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.